Journal article
In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease
VL Villemagne, S Furumoto, MT Fodero-Tavoletti, RS Mulligan, J Hodges, R Harada, P Yates, O Piguet, S Pejoska, V Doré, K Yanai, CL Masters, Y Kudo, CC Rowe, N Okamura
European Journal of Nuclear Medicine and Molecular Imaging | SPRINGER | Published : 2014
Abstract
Purpose: Diagnosis of tauopathies such as Alzheimer's disease (AD) still relies on post-mortem examination of the human brain. A non-invasive method of determining brain tau burden in vivo would allow a better understanding of the pathophysiology of tauopathies. The purpose of the study was to evaluate 18F-THK523 as a potential tau imaging tracer. Methods: Ten healthy elderly controls, three semantic dementia (SD) and ten AD patients underwent neuropsychological examination, MRI as well as 18F-THK523 and 11C-Pittsburgh compound B (PIB) positron emission tomography (PET) scans. Composite memory and non-memory scores, global and hippocampal brain volume, and partial volume-corrected tissue rat..
View full abstractRelated Projects (9)
Grants
Awarded by Japan Society for the Promotion of Science
Funding Acknowledgements
We thank Prof. Michael Woodward, Dr. John Merory, Dr. Gordon Chan, Dr. Kenneth Young, Dr. David Darby, Ms. Fiona Lamb and the Brain Research Institute for their assistance with this study. The study was partially supported by an Alzheimer Drug Discovery Foundation Research Grant (20101208 AFTD) and by a National Health and Medical Research Council of Australia Project Grant 1044361. The funding sources had no input into the design and conduct of the study; collection, management, analysis and interpretation of the data; and in the preparation, review, approval or decision to submit the manuscript for publication.